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INTRODUCTION 
 
Human neuroblastoma, a neoplasm of peripheral neural crest origin, is most common 
extracranial solid tumor of childhood and accounts for 15% of cancer deaths in children 
(1, 2). Despite recent advances in treatment options, aggressive neuroblastoma remains 
refractory to current therapy. The overall 5-years survival rate for patients with 
advanced-stage of neuroblastoma is 30-40% (3-5). Neuroblastoma patients harboring 
genomic MYCN amplification accompanied by allelic deletion of short arm of 
chromosome 1 are at high risk for unfavorable outcome. Amplification of the 
proto-oncogene MYCN occurs in up to 25% of neuroblastoma, strongly correlating to 
the advanced-stage disease and the failure of chemotherapy treatment (6-8). Loss of 
heterozygosity at 1p36 is found in 20%-40% of neuroblastoma cases and is 
independently associated with progression-free survival. Thus, it has been predicted that 
candidates of tumor suppressor gene may exist in this region (9-11).  
 
RUNX3 belongs to the Runt-related gene family, whose members are pivotal 
regulators of neuronal development (12, 13). RUNX3 is located at human 
chromosome 1p36 and its gene product acts as a tumor suppressor in various cancers 
(14-18) except neuroblastoma. A possible role of RUNX3 in neuroblastoma is 
suggested by its transcriptional regulation of TrkB, which was identified as an 
oncogene (19-22). While the most neuroblastoma cell lines do not synthesize RUNX3 
protein at detectable levels, exogenous expression of RUNX3 causes the cell death, 
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cell cycle arrest, or differentiation in neuroblastoma (23). In this study, I quantitatively 
measured the expression levels of RUNX3 in 110 primary neuroblastoma samples to 
test the hypothesis that the inactivation of RUNX3 is independently prognostic for 
adverse stages of the disease. Based on clinical analyses, investigation in vitro 
revealed a reliable mechanism by which RUNX3 inhibits the stability and oncogenic 
activity of MYCN in neuroblastoma.  
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MATERIALS AND METHODS 
 
Clinical specimens  
Tumor DNA and RNA samples were obtained from 110 tumor specimens in our 
Neuroblastoma Resource Bank at Chiba Cancer Center Research Institute. The 
specimens were kindly provided from various institutions and hospitals where informed 
consent was obtained. All tumors were diagnosed clinically as well as pathologically as 
neuroblastoma and staged according to the International Neuroblastoma Staging System 
(INSS) criteria. MYCN copy number, TRKA mRNA expression levels, and DNA index 
were measured as reported previously (24).  
 
Reverse transcription-PCR and real time PCR analyses 
Total RNA was prepared from the primary neuroblastoma tissues and cell lines, 
followed by the first strand synthesis. RT-PCR was performed according to the 
manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA). Quantitative real time 
PCR was carried out using SYBR GREEN method as the manufacturer described 
(Applied Biosystems, Foster City, CA, USA). 
RT-PCR primer sets used were as follows:  
MYCN (fw: aaattgaacacgctcggact; rv: aaccgtcaccaacgtttagc),  
RUNX3 (fw: cagaagctggaggaccagac; rv: tcggagaatgggttcagttc),  
P53 (fw: gttccgagagctgaatgact; rv: tctgagtcaggcccttctgt),  
CAD (fw: assasgacacctgaaagacc; rw: tactggtggtggagggtagc),  
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ODC1 (fw: taccgatcctgagaccttcg; rv: gttgattacgccggtgatct),  
ID2 (fw: catcttggacctgcagatcg; rw: atgaacaccgcttattcagc),  
MDM2 (fw: tctacagggacgccatcga; rw: ctgatccaaccaatcacctgaa),  
GAPDH (fw: accacagtccatgccatca; rv: tccaccaccctgttgctgta). 
Quantitative real time PCR primer sets used are as follows:  
RUNX3 primers (fw: ttcaaggtggtggcattgg; rv: ttgcctgccatcacagtca),  
MYCN (fw: ggacaccctgagcgattcag; rv: aggaggaacgccgcttct),  
GAPDH (fw: acctgacctgccgtctagaa; rv: tccaccaccctgttgctgta).  
 
Array-comparative Genomic Hybridization  
Array-CGH analysis was performed using UCSF BAC array (2464 BACs with 1 Mb 
resolution (average)) and 59 primary neuroblastomas identified as diploid were 
subjected to further analysis. Experimental procedures and the criteria for losses and 
gains were described previously (24, 41).  
 
Cell Culture and Transfection 
The human neuroblastoma cell lines (SK-N-BE, NLF) were maintained in RPMI 1640 
medium (Nissui, Tokyo, Japan) supplemented 10% heat-inactivated fetal bovine 
serum (Invitrogen) and 100 mg/ml of penicillin-streptomycin (Invitrogen). HeLa and 
HEK293 cells were cultivated in Dulbecco's modified Eagle's medium supplemented 
with 10% heat-inactivated fetal bovine serum (Invitrogen) and antibiotic mixture. 
Transient transfection was performed using Lipofectmine 2000 transfection reagent 
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(Invitrogen) according to the manufacturer's instructions. 
 
Immunoblotting, Immunoprecipitation and in vitro Translation-Coupled 
Pulldown Assay 
For immunoblotting, cells were lysed in a lysis buffer containing 25mM Tris-HCl, pH 
7.5, 137mM NaCl, 2.7mM KCl, 1%Triton X-100, and protease inhibitor mixture 
(Sigma, St. Louis, MO, USA), and spun to separate insoluble debris from the clear 
lysates. Equal amounts of cell lysates were separated by SDS-PAGE and transferred 
onto Immobilon-P membranes (Milipore, Bedford, MA, USA). The transferred 
membranes were incubated with monoclonal anti-MYC tag (9B11, Cell Signaling, 
Beverly, MA), polyclonal anti-HA tag (561-5, MBL, Woburn, MA, USA), 
monoclonal anti-MYCN (Ab-1, Oncogene Research Products, Cambridge, MA, USA), 
polyclonal anti-MYCN (9405, Cell Signaling), polyclonal anti-actin (20-33, Sigma), 
monoclonal anti-RUNX3 (R3-5G4, Abcam, Cambridge, UK), monoclonal 
anti-ubiquitin (FK-2, Enzo, Farmingdale, NY, USA) antibodies, followed by 
incubation with the appropriate horseradish peroxidase-conjugated secondary 
antibodies (Cell Signaling Technology, Beverly, MA, USA). For immunoprecipitation, 
the cell lysate of each sample contains total weight of approximately 600 ug of the 
protein that was extracted from 2x10^7 cells. The cell lysates were precleared with 30 
μl of protein G-Sepharose suspension (Amersham Biosciences AB, Corston, UK) and 
then incubated with anti-MYCN monoclonal antibody or anti-RUNX3 monoclonal 
antibody for 2h at 4°C. For in vitro translation-coupled pulldown assay, full length or 
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deletion constructs of MYC-tagged RUNX3 were transfected into HEK293 cells and 
the cell lysate was pre-purified by MYC-tag antibody and protein G-Sepharose beads. 
[
35
S] methionine-labeled MYCN was generated in the coupled 
transcription/translation system (Promega, Madison, WI, USA) and mixed with 
pre-purified RUNX3 proteins for 2h at 4°C. After purification, 
35
S-labeled bound 
proteins were analyzed by 10% SDS-PAGE and visualized by autoradiography. 
 
Immunofluorescence Analysis 
For immunofluorescence, SK-N-BE and HeLa cells were grown on coverslips and 
transfected with indicated expression plasmids, Forty-eight hours after transfection, 
cells were fixed in 100% methanol for 20min at -20°C, blocked in 3% bovine serum 
albumin, stained with the corresponding antibodies, and examined with a laser 
scanning confocal microscope. 
 
Protein Stability and Ubiquitination Assay 
Cells were harvested at different time points after pretreatment with cycloheximide 
(100 μg/ml), and the cell lysates were employed for immunoblotting. For 
ubiquitination assay, SK-N-BE cells were transfected with or without RUNX3. 
SK-N-BE cells were exposed to the proteasomal inhibitor MG132 (20 μM) for 6 
hours before harvest. Cell lysates were incubated with anti-MYCN or anti-ubiquitin 
monoclonal antibody.  
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Boyden Chamber Assay 
For the Boyden chamber assay, 50000 pre-transfected cells were resuspended in 
serum-free medium and plated in the top chamber of transwell inserts (Falcon, San 
Jose, CA, USA). After 24h of transfection, cells on the bottom surface of the insert 
were fixed in 10% formalin and stained with a crystal violet solution. Results shown 
are representative of three independent experiments. 
 
Cell Proliferation Assay 
Pre-transfected neuroblastoma cells were seeded in 96-well plates at a density of 10
3 
cells per well in a final volume of 100 μl. WST assay was performed according to the 
manufacturer’s instruction (Cell counting Kit-8; DOJINDO, Kumamoto, Japan).  
 
Colony Formation Assay 
SK-N-BE cells were seeded at a final density of 500,000 cells/6 cm plate and allowed 
to attach overnight. Total amount of plasmid DNA per transfection was kept constant 
(2 μg) with pcDNA3. 48h after transfection, cells were transferred to the fresh 
medium containing G418 (400 μg/ml). After 14 days, viable colonies were washed in 
PBS and stained with Giemsa solution. For colony formation assay utilizing soft agar 
(42), 2.5 × 10
3
 cells of the RUNX3 transfected or mock-transfected were seeded in 
triplicate in 35-mm cell culture plates containing 0.2% agar and RPMI 1640 
supplemented with 10% FBS. After 20 days, colonies with diameters >300 μm were 
scored as positive.   
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Construction of a Series of Deletion Mutants and a point mutant of RUNX3 
RUNX3 deletion mutants were amplified by PCR. PCR primers including EcoRI and 
BamHI restriction sites and the amplicons were subcloned into pcDNA3.1. The point 
mutated RUNX3-R122C was generated utilizing the QuikChange II XL site-directed 
mutagenesis kit (Agilent Technologies). The PCR fragments to construct these 
expression plasmids were verified by DNA sequencing. 
RUNX3 deletion mutants were amplified by PCR with the following primers:  
RUNX3 249  
fw: ccgaattcatggcatcgaacagcatcttc;  
rw: ccggatccttgccttggattggggtctg (1-747),  
RUNX3 200  
fw: ccgaattcatggcatcgaacagcatcttc;  
rw: ccggatccttcttctgccggtgccgtct  (1-600),  
RUNX3 D1-33  
fw: ccgaattccgccatgttcccctgcggcggc;  
rw: ccggatccttgtagggccgccacacggc (99-1290),  
RUNX3 D1-66  
fw: ccgaattccgccatgcgctcgatggtggac;  
rw: ccggatccttgtagggccgccacacggc (198-1290), 
RUNX3 D1-100  
fw: ccgaattccgccatgaagacgctgcccgtc;  
rw: ccggatccttgtagggccgccacacggc (300-1290), 
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RUNX3 D1-133  
fw: ccgaatccgccatggagctgcgcaatgcc;  
rw: ccggatccttgtagggccgccacacggc (399-1290), 
RUNX3 D1-166  
fw: ccgaattccgccatgaccatcactgtgttc;  
rw: ccggatccttgtagggccgccacacggc (498-1290),  
RUNX3 D1-200  
fw: ccgaattccgccatgctggaggaccagacc;  
rw: ccggatccttgtagggccgccacacggc (600-1290). 
The RUNX3-R122C was amplified by the mutagenic oligonucleotide primers:  
fw: gagaactactccgctgagctgtgcaatgcctcggccgtcatgaag;  
rw: cttcatgacggccgaggcattgcacagctcagcggagtagttctc.  
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RESULTS 
 
Decreased expression of RUNX3 is associated with poor prognosis in 
neuroblastoma patients 
Since the RUNX3 gene is mapped to chromosome 1p36.2 which is frequently deleted 
in unfavorable neuroblastomas as well as other cancers, I asked whether RUNX3 
could act as a tumor suppressor gene in neuroblastoma. I then examined the 
expression levels of RUNX3 mRNA in 16 favorable (stage 1 or 2, single copy of 
MYCN and high expression of TrkA ) and 16 unfavorable (stage 3 or 4, amplification 
of MYCN and low expression of TrkA ) neuroblastoma samples by semiquantitative 
RT-PCR (24-27). RUNX3 was expressed at higher levels in the favorable group than 
the unfavorable group (Fig. 1A). This result prompted me to quantitatively measure 
the expression levels of RUNX3 in 110 primary samples of neuroblastomas utilizing 
real time PCR. I found that RUNX3 expression levels in stage 1 and 2 patients tended 
to be higher (Fig. 1B). To further understand the impact of RUNX3 expression on 
patients outcome, I divided the clinical samples into two, such as RUNX3 high (n=22) 
and low (n=88) expression groups, based on the mean value of RUNX3 expression. 
Kaplan-Meier analysis showed that decreased expression of RUNX3 mRNA was 
significantly correlated with poor survival rate (p=0.016, Fig. 1C). In addition, the 
possible relationship between RUNX3 expression levels and various clinical and 
biological features from these samples were examined and summarized in Table 1. 
Significantly high levels of RUNX3 expression were found in the low-risk tumors 
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(stages 1, 2 and 4s, p<0.001). Statistical correlation was also detectable between 
RUNX3 expression and the copy number of MYCN (p=0.047). The log-rank test 
demonstrated that several prognostic factors, including RUNX3, were significantly 
correlated with clinical outcome in these 110 neuroblastoma patients (Table 2). The 
multivariate Cox regression analysis showed that RUNX3 mRNA expression levels 
are not significantly associated with patient’s survival only when INSS stages or 
MYCN copy number is employed (Models C and E in Table 3), suggesting that 
RUNX3 expression levels are associated with these two factors in terms of patients’ 
survivals.  
 
The relationship between chromosomal deletion at 1p36 and expression of 
RUNX3  
Since low expression of RUNX3 is correlated with poor patient’s outcome, I sought to 
identify the possible mechanism underlying the suppression of RUNX3 expression. 
According to the data obtained from array-CGH analysis using UCSF BAC array (2464 
BACs, -1 Mb resolution), among 59 samples that were identified as diploid tumors, 12 
tumors revealed to have a partial deletion at chromosome 1p36 (Table 4), indicating that 
RUNX3 expression is significantly lower in the tumor cells with 1p36 loss than those 
without the loss. These results suggest that the gene dosage effect is one of the reasons 
why RUNX3 expression is decreased in aggressive neuroblastomas. 
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The outcome relationship between RUNX3 and MYCN expressions in 
neuroblastoma patients 
As I mentioned above, amplification of MYCN was significantly associated with low 
expression of RUNX3. A real time PCR assay quantitatively measuring the expression 
levels of RUNX3 also supported this notion (Fig. 2A), as a majority of RUNX3 high 
expression cases was observed in the tumors with single copy of MYCN. Consistent 
with previous literatures (28), amplified MYCN is apparently related to fatal cases 
indicated by filled triangles in Fig. 2A. Indeed, the Kaplan-Meier survival plot clearly 
demonstrated that the patients with amplified copies of MYCN die more quickly than 
those with a single copy (Fig. 2B). These results lead me to the hypothesis that 
amplified copies of MYCN gene induce higher level of MYCN mRNA expression and 
high MYC pathway activity, resulted in death of neuroblastoma patients in which 
RUNX3 is expressed in a low level. To test this possibility, the expression levels of 
MYCN in the primary neuroblastoma samples were quantitatively measured by a real 
time PCR and were compared with RUNX3 levels (Fig. 2C). Nearly all stage 4 tumors 
were fatal cases (shown by filled triangles in Fig. 2C) and were associated with higher 
MYCN and lower RUNX3 expressions (Fig. 2C, left panels). In contrast, survivals were 
enriched in lower INSS stages (1 and 2) and were generally accompanied by lower 
MYCN and higher RUNX3 expressions. Next, the primary neuroblastoma samples were 
arranged according to the expression levels of MYCN to further elucidate the correlation 
between MYCN and RUNX3 expressions (Fig. 2C, right panels). Primary samples were 
classified into two groups using the mean value of MYCN as the cutoff value. I found 
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that, among the MYCN high expression group, patients with higher expression levels of 
RUNX3 tend to survive, while those with low expression died (Fig. 2C, inset in right 
panels). Kaplan-Meier plot of the primary samples in which MYCN is highly expressed 
also supports this notion (Fig. 2D). This result suggests that RUNX3 high expression is 
closely associated with survival possibility of neuroblastoma patients, even though 
some of them expressed high level of MYCN.  
 
The biological function of RUNX3 in neuroblastoma cells 
The clinical study above promoted me to further investigate the function of RUNX3 
in neuroblastoma cell lines. SK-N-BE (MYCN amplified) cells were transiently 
transfected with empty vector or increasing amounts of RUNX3 expression vector 
and the cell growth was examined by WST assay and colony formation assay. 
RUNX3 overexpression decreased the growth rate in a dose dependent manner (Fig. 
3A). Similar results were obtained by conventional colony formation assay (Fig. 3B). 
Furthermore, colony formation assay utilizing soft agar demonstrated that 
overexpression of RUNX3 decreased anchorage independent cell growth, suggesting 
that RUNX3 could inhibit the oncogenic property of neuroblastoma-derived cell line 
(Fig. 3C). In order to better understand the changes in the cellular phenotype mediated 
by RUNX3, I tested whether RUNX3 had any role in regulating the cell migration of 
neuroblastoma. Toward this, Boyden chamber migration assay was performed. 
Overexpression of RUNX3 decreased the number of cells that migrate to the lower 
side of the membrane, while the transfection of an empty vector did not (Fig. 3D). 
Results 
 17 
This result indicates that RUNX3 inhibits the migration activity of 
neuroblastoma-derived cell line.  
 
RUNX3 overexpression reduces MYCN expression at protein level in 
neuroblastoma cells 
Since there was a close correlation between high expression of RUNX3 and 
favourable outcome in neuroblastoma patients in which MYCN is highly expressed, I 
hypothesized that RUNX3 may negatively regulate MYCN oncogenic activities, 
resulting in survival of neuroblastoma patients. Thus, I examined whether RUNX3 
could control MYCN expression at either mRNA or protein level. Overexpression of 
RUNX3 decreased the MYCN proteins in a dose- and time-dependent manner (Fig. 
4A, top panel and Fig. 4B), while RT-PCR showed that the mRNA expression level of 
MYCN was not affected by the exogenous RUNX3 overexpression (Fig. 4A, bottom 
panel). Essentially similar results were obtained utilizing another MYCN amplified 
neuroblastoma cell line NLF. These data indicate that RUNX3 reduced the expression 
of MYCN at protein level rather than mRNA level, suggesting that RUNX3 
negatively regulates MYCN expression by the post-translational mechanism. 
Immunofluorescence microscopy demonstrated that the cells in which exogenous 
RUNX3 (red) was overexpressed showed less degree of endogenous MYCN (green) 
(Fig. 4C, top panels), indicating that exogenous RUNX3 and endogenous MYCN are 
mutually exclusive in terms of the protein expression pattern. I further examined the 
number of cells that have different expression patterns of RUNX3 and MYCN. 
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Majority of the cells show either MYCN or RUNX3 expressions, and less than 10% 
of cells express both or none (Fig. 4C, bottom panel). These results demonstrated that, 
at protein level, MYCN is inversely correlated with RUNX3 expression. In order to 
investigate reduction of MYCN protein in detail, the degradation rate of endogenous 
MYCN in the absence or presence of RUNX3 was compared. Cycloheximide was 
used to inhibit the synthesis of new MYCN protein. Immunoblotting showed that the 
degradation of MYCN was accelerated by RUNX3 (Fig. 4D), suggesting a negative 
regulation of RUNX3 on MYCN stability. Since RUNX3 is a transcription factor, 
degradation of MYCN may be a secondary effect of the transcriptional activation 
mediated by RUNX3. To exclude out this possibility, I employed RUNX3-R122C, a 
transcriptionally incompetent mutant of RUNX3 (29, 30), to test whether the 
transcriptional activity of RUNX3 is essential or not for the degradation of MYCN. 
Both RUNX3 wild type (WT) and RUNX3-R122C were able to facilitate the 
degradation of MYCN (Fig. 4E), suggesting that the transcriptional activity of 
RUNX3 is not necessary. Therefore, I concluded that the protein degradation of 
MYCN is directly mediated by RUNX3.  
 
RUNX3 promotes ubiquitination of MYCN, resulting in MYCN degradation 
The protein stability of MYCN is regulated by a complex signaling network and the 
degradation of MYCN is mainly promoted by an ubiquitin-proteasome pathway 
(31-33). Thus, I investigated the protein stability of MYCN in the presence or absence 
of proteasome inhibitor MG132. Immunoblotting showed that the overexpression of 
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RUNX3 decreased endogenous MYCN in a dose dependent manner, and this decrease 
was inhibited by an MG132 treatment (Fig. 5A, left panel). This result suggests that 
destabilization of MYCN mediated by RUNX3 depends on the proteasomal function. 
Similar results were obtained in another neuroblastoma cell line NLF (Fig. 5A, right 
panel). Since the MYCN proteolysis occurs through the proteasome pathway, I asked 
whether ubiquitination is involved in this process. In the presence of MG132, RUNX3 
efficiently facilitated the polyubiquitination of MYCN (Fig. 5B, top panel). Similarly, 
increasing polyubiquitination of MYCN was detected in the cell lysate 
immunoprecipitated by anti-MYCN antibody followed by immunoblotting with 
anti-ubiquitin antibody (Fig. 5B, bottom panel). Taken together, these results suggest 
that RUNX3 destabilizes MYCN through the ubiquitin-proteasome pathway.  
 
Physical interaction between RUNX3 and MYCN 
As shown above, the transcriptionally deficient mutant RUNX3-R122C can also 
induce the degradation of MYCN as efficiently as wild-type RUNX3, suggesting that 
the transcriptional activity of RUNX3 is unnecessary in this process. Therefore, I 
speculated that RUNX3 may directly interact with MYCN to induce its degradation. 
To confirm this postulation, first I examined the potential interaction between 
exogenous RUNX3 and MYCN. HeLa cells were transiently co-transfected with 
expression plasmids of MYC-tagged RUNX3 (RUNX3-MYC) and HA-tagged 
MYCN (HA-MYCN). Anti-MYC tag antibody precipitated RUNX3-MYC and 
HA-MYCN. As well, anti-HA tag antibody precipitated HA-MYCN and 
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RUNX3-MYC, confirming that RUNX3 and MYCN could interact with each other. 
Furthermore, the interaction between endogenous proteins was confirmed in 
SK-N-BE cells (Fig. 6B). Since RUNX3-R122C induces the destabilization of MYCN, 
we also investigated whether RUNX3-R122C could bind to MYCN. I found that 
RUNX3-R122C co-immunoprecipitated with endogenous MYCN (Fig. 6C), 
suggesting that the interaction between RUNX3 and MYCN is important in the 
process of MYCN degradation. To identify the regions of RUNX3 required for the 
interaction with MYCN, in vitro translation-coupled pull down assay was performed 
(Fig. 6D). Plasmids expressing a series of deletion mutants of RUNX3 protein were 
tranfected into HEK293 cells. Radiolabeled MYCN bound to the full length as well as 
several deletion constructs containing intact runt domain (Deletion constructs 249, 
200, 1-33, and  1-66). However, deletion constructs containing partial runt domain 
(1-100, 1-133, and  1-166) failed to bind to MYCN, suggesting that the 
N-terminal side of the runt domain is responsible for MYCN-RUNX3 interaction. 
Interestingly, a deletion construct fully lacking the runt domain ( 1-200) retained the 
interaction capability. It was assumed that transactivation domain is also capable of 
MYCN interaction and the C-terminal side of the runt domain interferes it. When 
RUNX3-MYC and HA-MYCN were co-overexpressed, I observed colocalization of 
these exogenous proteins in the nucleus after 24 hours of transfection, further 
supporting my notion (Fig. 6E). Taken together, these results suggest that RUNX3 and 
MYCN physically interact through the runt domain of RUNX3. 
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RUNX3 suppresses the expression of MYCN target genes  
Considering the degradation of MYCN acting as a transcription factor in 
neuroblastoma (31, 34), I predicted that RUNX3 may also inhibit the expression of 
genes targeted by MYCN. To confirm this, SK-N-BE cells were transfected with 
increasing amounts of RUNX3 expression plasmid. RT-PCR demonstrated that the 
expression levels of mRNA of MYCN target genes, such as MDM2, ID2, and P53, 
(35-37) were decreased, while mRNA of endogenous MYCN was not affected (Fig. 
7A). As well, overexpression of RUNX3 could overcome even exogenous MYCN to 
suppress the target genes (MDM2, ODC1, and CAD) in HeLa cells (Fig. 7B). Finally, 
I employed a couple of deletion mutants of RUNX3 (Fig. 6D) to confirm the notion 
above. RUNX3 full length (FL) and 1-66 induced protein degradation of MYCN as 
well as suppression of MYCN target genes, MDM2 and CAD (Fig. 7C). However, 
unbound mutants (1-100 and 1-200) induced neither MYCN degradation nor gene 
suppression. It should be noted that one of the deletion mutants (200) also failed to 
induce degradation and suppression, while it still binds to MYCN (Fig. 6D). The 
deletion mutant 200 is the C-terminally truncated form of RUNX3 completely lacking 
the transactivation domain. Since previous literatures demonstrated that this form of 
truncated RUNX3 lost tumor suppression capability (38, 39), I assume that this 
deletion mutant cannot recruit additional factors required for the MYCN degradation, 
even though it can interact with MYCN in vitro. These results clearly demonstrated 
that RUNX3 inhibits transcriptional activation of MYCN target genes, suggesting that 
RUNX3 can block the oncogenic signaling pathway mediated by MYCN.  
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DISCUSSION 
 
In this study, I found that RUNX3 could overcome oncogenic behavior of MYCN. 
Consistent with my findings, RUNX3 induces the degradation of estrogen receptor α 
(ERα) and acts as a tumor suppressor in breast cancer (15). Thus, I concluded that 
RUNX3 destabilizes oncogenic proteins, such as ERα and MYCN, to exert its tumor 
suppressive function.  
 
Threonine 50 (T50) and serine 54 (S54) are critical amino acid residues responsible 
for instability of MYCN. Initial monophosphorylation at S54 by cyclin B/cdk1 
stabilizes MYCN, and primes MYCN for a second phosphorylation at T50 controlled 
by glycogen synthase kinase 3β (GSK-3β). MYCN protein monophosphorylated at 
T50 binds to E3 ligase Fbxw7 followed by ubiquitination and degradation (31-33, 40). 
Early report suggested that RUNX3 transcriptionally inhibits AKT expression and 
therefore promotes GSK-3β activation in the gastric cancer cell lines (17). However, 
we did not detect the induction of GSK-3β expression by RUNX3 in neuroblastoma 
cell line (data not shown). Rather, I showed that the transcriptionally incompetent 
mutant of RUNX3 could induce the degradation of MYCN, suggesting that the 
transcriptional activity of RUNX3 is not essential for MYCN degradation. 
Considering the interaction between RUNX3 and MYCN, it is possible that RUNX3 
might recruit an E3 ubiquitin ligase and forms a protein complex to induce the 
degradation of MYCN, resulting in suppression of the transcriptional targets of 
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MYCN. These results explain the molecular mechanism of higher survival rate 
observed in neuroblastoma patients in whom both MYCN and RUNX3 are highly 
expressed. We hypothesized that high expression of RUNX3 induces the 
proteasome-mediated degradation of MYCN and inhibits the MYCN oncogenic 
function, which contributes to the favorable outcome. In addition, as I demonstrated 
by cellular migration and soft agar assay, RUNX3 overexpression reduced the cellular 
mobility as well as anchorage independent cell growth. Since these are typical 
indicators of the tumor-specific property of the cell lines, it was assumed that RUNX3 
overexpression improves the survival rate of the patients by inhibiting the oncogenic 
properties of the tumor cells.  
 
RUNX3 is located at 1p36 where nearly 30% of neuroblastoma cases had a deletion 
(3-5). Consistently, I found a positive correlation between low expression of RUNX3 
and the 1p36 loss. While it has been reported that RUNX3 is inactivated by 
hypermethylation at its promoter region in various cancers (12-14), I did not find 
statistically significant correlation between the methylation status and mRNA 
expression levels of RUNX3 in 110 primary neuroblastoma samples (data not shown). 
RUNX3 transcription factor plays pivotal roles in neural development and, as far as 
we examined, RUNX3 expression is very low in the majority of neuroblastoma cell 
lines available. Therefore, I mainly employed overexpression system, rather than 
knockdown strategy of RUNX3. Such low level of RUNX3 could be necessary to 
establish the neuroblastoma cell line in which MYCN gene is amplified. I further 
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assume that chromosomal 1p deletion is one of the major reasons responsible for the 
low RUNX3 expression in both primary tumors and cell lines of neuroblastoma.  
 
Taken together, I demonstrated that RUNX3 acts as a tumor suppressor gene in 
neuroblastoma. Activation of RUNX3 may suppress MYCN-mediated downstream 
signaling pathway. I therefore believe that the analysis of RUNX3 expression are 
useful for identifying low risk neuroblastoma that are initially diagnosed as high risk 
and mostly increase the prognostic sensitivity.  
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FIGURE LEGENDS 
 
Figure 1.  
Expression levels of RUNX3 in primary neuroblastomas.  
(A) Semi-quantitative RT-PCR analysis. Total RNA was prepared from primary samples 
with better prognosis (stages 1 and 2, MYCN single copy, n = 16) and those with poor 
prognosis (stages 3 and 4, MYCN amplified, n = 16). RT-PCR was performed to 
examine the expression levels of RUNX3. GAPDH is employed for loading control.  
(B) Quantitative real time PCR analysis. The relative expression levels of RUNX3 in 
primary samples (stage 1, 2, 3, 4, and 4S) are shown. RUNX3 levels were standardized 
using the corresponding GAPDH value of each neuroblastoma sample. Filled triangles 
indicate fatal cases due to neuroblastoma cancer.  
(C) Kaplan-Meier survival curves of patients with neuroblastoma. Expression levels of 
RUNX3 in 110 primary neuroblastoma samples determined by real time PCR were 
classified into two categories, such as High (open circle, n = 22) and Low (filled circle, 
n = 88) expression groups, based on the mean value of RUNX3 expression levels.  
 
Figure 2.  
Inverse correlation between RUNX3 and MYCN expression.  
Filled triangles shown in each panel indicate fatal cases due to neuroblastoma cancer.  
(A) Quantitative real time PCR of RUNX3 expression. Primary samples are classified 
into two groups based on the copy number of MYCN gene (single copy or amplified).   
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(B) Kaplan-Meier survival plot according to a copy number of MYCN. 108 primary 
neuroblastomas were classified into two categories (Single or Amplified).  
(C) The expression levels of RUNX3 (top panels) and MYCN (bottom panels). Primary 
neuroblastoma samples are arranged according to stages (left panels) or relative MYCN 
expression values (right panels). RUNX3 expression levels associated with high 
expression levels of MYCN are shown in detail (inset). Arrowheads indicate the 
survivals in which both RUNX3 and MYCN were highly expressed.  
(D) Kaplan-Meier survival plot according to RUNX3 expression levels. 20 primary 
neuroblastomas in which MYCN is highly expressed were classified into two categories, 
such as High (open circle, n = 4) and Low (filled circle, n = 16) RUNX3 expression 
groups, based on the mean value of RUNX3 expression levels. 
 
Figure 3.  
Transient transfection of RUNX3 suppresses the growth and migration of 
neuroblastoma cells. 
(A) WST assay. Empty vector or increasing amounts of RUNX3 expression plasmid 
were transfected into SK-N-BE cells. Cell growth was measured at indicated hours. 
The expression of exogenous RUNX3 was shown by immunoblotting (bottom 
panels).  
(B) Colony formation assay. SK-N-BE cells were transfected with increasing amounts 
of RUNX3 expression plasmid (0.5, 1, and 2 μg). Total amounts of plasmid DNA per 
transfection were kept constant (2 μg) with empty vector. The histograms represent 
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the number of colonies in each group. Representative colony formation images are 
also shown.  
(C) Soft agar assay. SK-N-BE cells were transfected by either mock or 
RUNX3-expression vector. The cells were seeded onto soft agar plates in triplicate 
[*].The histograms represent the number of colonies (diameters >300 μm) in each 
plate. Representative colony images are also shown.   
(D) Boyden chamber assay. Empty vector or RUNX3 expression plasmid was 
transfected into SK-N-BE cells. Numbers of migrated cells were counted and are 
represented as relative values. Control group was set to 1. Error bars represent the 
standard deviation obtained from triplicate experiments.   
 
Figure 4.  
RUNX3 overexpression reduces the protein level of MYCN in neuroblastoma 
cells. 
(A) RUNX3 inhibits MYCN expression at protein level. SK-N-BE and NLF cells 
were transfected with empty vector or increasing amounts of RUNX3 expressing 
plasmid. Whole cell lysates and total RNA were subjected to immunoblotting (IB) 
(top panels) or RT-PCR (bottom panels), respectively. Actin and GAPDH were used 
as loading controls.  
(B) Time Course. SK-N-BE cells were transfected with RUNX3 expressing plasmid. 
Cell lysates were prepared at indicated time points and were subjected to 
immunoblotting.  
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(C) The subcellular localization of RUNX3 and MYCN are detected by 
immunofluorescent staining in SK-N-BE cells. Exogenous RUNX3 and endogenous 
MYCN were stained by anti-MYC tag (red) or anti-MYCN (green) antibodies, 
respectively. Nucleus was visualized by DAPI staining. The histogram represents the 
number of cells expressing indicated genes (n= 100). 
(D) RUNX3 decreases the half-life of MYCN. Empty vector or RUNX3 expressing 
plasmid was transfected into SK-N-BE cells, and the cells were treated with 
cycloheximide (CHX) and harvested at the indicated time points. 40 ug (the cells 
transfected with empty vector) or 60 ug (the cells with RUNX3 expression vector) of 
the cell lysate was employed, respectively.  
(E) MYCN degradation mediated by wild-type RUNX3 and transcriptionally deficient 
mutant RUNX3-R122C. SK-N-BE cells were transfected with empty vector, RUNX3 
or point mutated RUNX3-R122C expressing plasmid.  
 
Figure 5.  
RUNX3 promotes ubiquitination of MYCN, resulting in MYCN degradation. 
(A) RUNX3-mediated MYCN degradation depends on proteasome function. 
Increasing amounts of RUNX3 expression plasmid (0, 2, and 4 μg) were transfected 
into SK-N-BE or NLF cells. MG132 (20 μM) was added to block proteasomal 
degradation. 
(B) RUNX3 induces poly-ubiquitination of MYCN. Increasing amounts of RUNX3 
expression plasmid were transfected into SK-N-BE cells. Cells were treated with 
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MG132. Whole cell lysates were immunoprecipitated with anti-ubiquitin antibody and 
analyzed by immunoblotting with anti-MYCN antibody (top panel). The same cell 
lysates were immunoprecipitated with anti-MYCN antibody and analyzed by 
immunoblotting with anti-ubiquitin antibody (bottom panel). 
 
Figure 6.  
Physical interaction between RUNX3 and MYCN. 
(A) Exogenous MYCN and RUNX3 interact in HeLa cells. HA-tagged MYCN was 
co-expressed with MYC-tagged RUNX3 in HeLa cells. Cells were treated with 
MG132 to inhibit the MYCN degradation. Cell lysates were immunoprecipitated with 
mouse IgG or anti-HA tag antibody and immunoblotted with anti-MYCN antibody 
and anti-RUNX3 antibody (left panels). The cell lysates were immunoprecipitated 
with mouse IgG or anti-MYC tag antibody and immunoblotted with anti-RUNX3 
antibody and anti-MYCN antibody (right panels). 
(B) Interaction between endogenous RUNX3 and MYCN. SK-N-BE cells were 
treated with MG132. Whole cell lysates were subjected to immunoprecipitation with 
anti-RUNX3 antibody (left panels) or anti-MYCN antibody (right panels), followed 
by immunoblotting with anti-MYCN and anti-RUNX3 antibody, respectively. 
(C) Both RUNX3 and RUNX3-R122C interact with endogenous MYCN in SK-N-BE 
cells. MYC-tagged RUNX3 and MYC-tagged RUNX3-R122C expression plasmids 
were transfected into SK-N-BE cells. After MG132 treatment, whole cell lysates were 
subjected to immunoprecipitation with anti-MYC tag antibody followed by 
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immunoblotting with anti-MYCN and anti-RUNX3 antibody.  
(D) in vitro translation-coupled pulldown assay. The schematic diagram (top panel) 
represents full length and a series of deletion constructs of RUNX3. Runt domain 
(open box) and transactivation domain (shaded box) are indicated. Overexpression of 
full length and deletion mutants of RUNX3 in HEK293 cells were confirmed by 
anti-Myc tag antibody on western blotting (middle panel). 
35
S-labeled MYCN pulled 
down by these RUNX3 constructs were detected by autoradiography (bottom panel).  
(E) Co-localization of RUNX3 and MYCN in the nucleus by immunofluorescent 
staining. HeLa cells were transfected with MYC-tagged RUNX3 (1 μg) and 
HA-tagged MYCN (4 μg), and were incubated with MG132. Each nucleus was 
visualized by DAPI staining. Exogenous RUNX3 and MYCN were detected in the 
nucleus by anti-MYC tag (red) and anti-HA tag (green) antibodies. Proteosome 
inhibitor MG132 was employed to inhibit MYCN degradation when RUNX3 was 
overexpressed. 
 
Figure 7.  
RUNX3 suppresses the expression of genes targeted by MYCN. 
(A) RUNX3 inhibits the expression of MYCN target genes. SK-N-BE cells were 
transfected with RUNX3 expressing plasmid. Total RNA was used for RT-PCR. 
(B) RUNX3 inhibits the transactivation ability of exogenous MYCN. HeLa cells were 
cotransfected with indicated combinations of expression plasmids. Whole cell lysates 
and total RNA were subjected to immunoblotting (IB) (upper panels) or RT-PCR 
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(lower panels), respectively. Actin and GAPDH were used as loading controls.  
(C) Unbound mutants of RUNX3 failed to induce MYCN degradation and 
transcriptional activation of MYCN target genes. SK-N-BE cells were transfected 
with indicated expression plasmids. Whole cell lysates and total RNA were subjected 
to immunoblotting (IB) (upper panels) or RT-PCR (lower panels), respectively.  
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